When grouped (48), these biomarkers identified NASH in patients with MAFLD/NAFLD who had normal ALT levels and those requiring liver biopsy, with an AUROC of 0.85 (48). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.